Amsterdam, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present at the Leerink Partners Rare Disease Roundtable Conference, October 1st, 2014, to be held at the Le Parker Meridien Hotel, New York City, NY, USA.
Date: October 1, 2014
Time: 8:50 a.m. (EDT)
Location: Le Parker Meridien Hotel, New York City, NY, USA
Speaking for uniQure: Joern Aldag, Chief Executive Officer
To access a simultaneous webcast of Mr. Aldag's presentation via the internet, log on to the "Events" section on the Media page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/.
A replay of the webcast will be available from uniQure's website for 30 days following the respective conference. Mr. Aldag's presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of uniQure's website at http://www.uniqure.com/news/calendar-of-events/.
About uniQure
uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com
uniQure:
Aicha Diba
Investor Relations
Direct: +31 20 240 8014
Main: +31 20 566 7394
IR@uniQure.com
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +1 781 235 3060
gschweitzer@macbiocom.com
HUG#1858300